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Abstract: Two common methods have been used to evaluate the in vitro bioactivity of bioceramics for the application of bone repair. 
One is to evaluate the ability of apatite formation by soaking ceramics in simulated body fluids (SBF); the other method is to evaluate 
the effect of ceramics on osteogenic differentiation using cell experiments. Both methods have their own drawbacks in evaluating the 
in vitro bioactivity of bioceramics. In this commentary paper we review the application of both methods in bioactivity of bioceramics 
and conclude that (i) SBF method is an efficient method to investigate the in vitro bioactivity of silicate-based bioceramics, (ii) cellular 
bioactivity of bioceramics should be investigated by evaluating their stimulatory ability using standard bioceramics as controls; and 
(iii) the combination of these two methods to evaluate the in vitro bioactivity of bioceramics can improve the screening efficiency for 
the selection of bioactive ceramics for bone regeneration.
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Introduction
The bioactivity of ceramics has been defined as “the 
bond ability with host bone tissue”.1 This includes 
enhancing the ability of apatite formation, osteoblast 
differentiation and bone matrix formation. Current 
bioceramics, such as hydroxyapatite, β-tricalcium 
phosphate (β-TCP), HAp/β-TCP and bioglass 45S5® 
have been widely used as bone repair materials, 
mainly due to their excellent bioactivity which makes 
them capable of bonding closely with the host bone 
tissue. The main disadvantage of these bioceramics is 
their relatively low mechanical strength, particularly 
low fracture toughness, which limits their application 
to only low-load bearing areas in the human body. 
To develop new bioactive ceramics for load bearing 
bone repair applications, it is important to understand 
the bonding of ceramics to living bone and methods 
to test bonding abilities.2 In order to avoid the high 
cost of in vivo experiment, several in vitro tests have 
been used to predict the in vivo bone bioactivity of 
bioceramics. However, there is still challenging 
to evaluate the in vitro bioactivity of bioceramics. 
Currently, two common methods have been used for 
testing the in vitro bioactivity of bioceramics. One 
method is to evaluate the apatite-formation ability 
of bioceramics in the simulated body fluids (SBF).2–4 
The other method is to investigate in vitro bone 
cell response to bioceramics.5–7 To evaluate apatite 
formation, Kokubo and colleagues have established a 
method to examine the apatite formation on materials 
in SBF. This method is useful prior to doing in vivo 
bone bioactivity experiments and can significantly 
reduce the number of animals needed for in vivo 
evaluation.2 However, Bohner and colleagues recently 
published a study which showed that there is currently 
not enough scientific evidence to support Kokubo’s 
claims that SBF is a useful tool to evaluate the in vitro 
bioactivity, and that the choice of SBF solution for 
testing the in vitro bioactivity of bioceramics is quite 
arbitrary.8 As for the cell experiment method, a large 
part of the scientific community has accepted the 
paradigm that in vitro cell testing can be used to test 
the in vitro bioactivity of bioceramics. This method 
has been widely used in testing the bioactivity of 
bioceramics. However, there are a number of cases 
indicating that using cell experiments to evaluate the 
in vitro bioactivity of bioceramics are not sufficient.9–12 
The methods for evaluating the in vitro bioactivity of 
bioceramics are still not clear. Therefore, the aim of 
this commentary paper is to present our view of how 
best to evaluate in vitro bioactivity of bioceramics.
comments for the In Vitro Bioactivity 
of Bioceramics
Firstly, the SBF method is a useful way to test the 
in vitro bioactivity of bioceramics for the assessment of 
the apatite formation potential. However, the reliability 
this method depends on the category of bioceramics 
tested. Silicate-based bioceramics, including 
silicate bioglass 45S5@,1 wollastonite (CaSiO3),
4,13 
akermanite (Ca2MgSi2O7) (See Fig. 1)
3 and diopside 
(Ca2MgSi2O6)
14 ceramics, have been shown to have 
excellent apatite forming abilities in SBF. Other studies 
also showed that these silicate ceramics possess good 
in vivo bioactivity,15–18 which indicates that SBF 
testing is an efficient method to evaluate their in vitro 
bioactivity. Phosphate-based bioceramics (HAp and 
β-TCP),19–21 carbonate-based bioceramics (coral, 
CaCO3), and sulfate-based materials (CaSO4), have 
no obvious apatite formation when soaked in SBF 
for a short time. They do, however, have excellent 
in vivo bone formation abilities,22,23 but this suggests 
that SBF alone is not sufficient to test the in vitro 
bioactivity for these three bioceramics. The SBF 
method, therefore, is useful for evaluating the in vitro 
bioactivity of silicate ceramics, but not for other types 
of bioceramics. The possible reason for this is that 
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Figure 1. Apatite formation on akermanite ceramics after soaking in SBF 
10 days.
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the biochemistry of in vivo bone formation of these 
bioceramics is significantly different. Silicate-based 
bioceramics bond with host bone via the formation of 
bone-like apatite layers due to the dissolution Ca2+ or 
other metal ions, followed by the deposition of Ca-P 
in the body.1,17,24,25 The phenomenon of dissolution and 
deposition does in fact happen in the SBF solution for 
silicate-based bioceramics. Sintered HAp and β-TCP 
ceramics can also bond directly with host bone.15,21,26 
Their apatite-formation ability mainly depends on 
their crystanillity and sintering property. Fully sintered 
HAp bulk ceramics are difficult to induce bone-apatite 
formation,19,20 and sintered β-TCP ceramics exhibit a 
poor ability of inducing apatite formation;27 however, 
HAp particles can induce apatite formation.28 CaCO3 
and CaSO4 materials bond to living bone, which may 
be related to their high resorbability.2
Secondly, cell experiments have been used widely 
to investigate the in vitro bioactivity of bioceramics. 
It is known that Al2O3, ZrO2, TiO2, and Mg2SiO4 
bioceramics have been considered as bioinert 
ceramics since they cannot induce apatite formation 
in SBF. They do, however, support bone cell 
attachment, proliferation and differentiation.9–12,29,30 
There are therefore a number of ceramics which 
elicits excellent cell responses; however, this does 
not necessarily translate into good in vivo bioactivity. 
On the contrary, some ceramics, such as highly 
degradable CaSiO3 ceramics, are detrimental to the 
in vitro growth of human osteoblasts due to their high 
rate of dissolution which results in a high localized 
pH environment.7,31,32 On the other hand, recent 
studies have shown that CaSiO3 ceramics possess 
excellent in vivo bone-formation ability and their 
in vivo bioactivity is greater than that of β-TCP.17 Cell 
based experiments to evaluate in vitro bioactivity of 
bioceramics are therefore not completely reliable. 
In addition, if cell cultures are used to evaluate the 
in vitro bioactivity of bioceramics, one should also 
investigate if the same bioceramics have the ability 
to stimulate or enhance a cell response. The selection 
of positive control materials to compare the cellular 
response is therefore important. Previous studies 
have selected β-TCP ceramics as the control material 
to compare the osteoblast response to akermanite 
(Ca2MgSi2O7) bioceramics.
6,33 It is necessary to know 
that the standard β-TCP ceramics has been carefully 
prepared by a standardized method and procedure, 
since the β-TCP ceramics can be prepared by a 
number of methods and these will affect different 
cell responses. Other studies have used blank tissue 
culture plate as control and to show that the ionic 
products of bioglass,5 akermanite,3 Sr-CaSiO3
13 and 
hardystonite (Ca2ZnSi2O7)
34 ceramics stimulate 
osteoblast proliferation. Tissue culture plate can 
therefore be regarded as one of the standard controls 
to evaluate in vitro bioactivity of bioceramics.
Thirdly, combining SBF and cell experiments 
to evaluate the in vitro bioactivity of bioceramics 
may be the better option. This is because if a novel 
bioceramic not only has the ability to induce apatite 
deposition in SBF, but also stimulates a cell response, 
such a bioceramic would most likely possess excellent 
in vivo bioactivity as well. Our own work has shown 
that akermanite ceramics has excellent apatite-forming 
abilities in SBF3 and significantly enhances in vitro 
osteoblast attachment (See Fig. 2), proliferation, 
differentiation and gene express compared to β-TCP 
ceramics,6 and in vivo experiments have confirmed 
that they also have excellent bone-forming abilities 
in animal tests.16 Another example is 45S5 bioglass, 
which possesses good apatite-formation ability35 
and supports osteoblast attachment, furthermore, the 
ionic products released from 45S5 bioglass stimulate 
osteoblast proliferation, differentiation, mineralization 
and osteogenic gene expression.5,36–38 The in vivo 
experiment has also shown that 45S5 bioglass has 
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Figure 2. osteoblast-like cells growing on the surface of akermnaite 
ceramics after 7 days of culture.
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excellent bone bond ability to be used as a bone repair 
material.1,15,39
conclusions
Selection of methods for the evaluation of in vitro 
bioactivity of bioceramics depends on the composition 
of bioceramics and the mechanism of their bone 
formation. The synthetic body fluid method is a 
useful approach to evaluate the in vitro bioactivity of 
silicate-based bioceramics. Cell based experiments is 
also a valuable test for bioactivity of bioceramics, but 
relevant standard materials should be considered as 
positive control. We recommend the combination of 
SBF and cell testing methods to evaluate the in vitro 
bioactivity of bioceramics, an approach which will 
improve the efficiency of screening bioceramics for 
further in vivo evaluation of bone repair.
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